Halozyme Therapeutics (HALO) announced that Bristol Myers Squibb (BMY) received a positive opinion from the Committee for Medicinal Products ...

Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications ...

We recently published a list of 10 Firms End Friday Strong; 3 Reach All-Time Highs. In this article, we are going to take a ...

Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...

Bristol Myers (BMY) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

EMA committee recommends approval of Bristol Myers Squibb’s subcutaneous formulation of Opdivo across multiple solid tumour indications: Princeton, New Jersey Monday, March 31, ...

Trump also nominated Republican attorney Thomas March Bell to lead the Department of Health and Human Service’s Office of Inspector General. Calley Means, a chronic disease entrepreneur and ...

Bristol Myers Squibb said a key European regulatory ... Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of a ...

Bristol Myers Squibb (BMS) has announced that its Opdivo (nivolumab) perioperative treatment regimen has been recommended by the European Medicines Agency’s human medicines committee for adults with ...

Bristol Myers Squibb said a key European regulatory committee is backing a formulation of its blockbuster cancer drug Opdivo that can be injected under the skin.

Princeton: Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...